ESC Congress 2024 — FFR-guided PCI improves outcomes in TAVI patients with coronary artery disease.

Principal investigator, Prof Jacob Thomsen Lønborg (Rigshospitalet, DK) joins us to discuss the NOTION-3 trial (NCT03058627).  
A multinational, open-label, investigator-initiated trial evaluated the efficacy of FFR-guided PCI versus medical therapy in managing coronary artery disease (CAD) among patients undergoing TAVI. The study enrolled 454 patients with severe aortic stenosis selected for TAVI by a multidisciplinary heart team. Patients exhibited at least one coronary stenosis with an FFR ≤ 0.80 or a diameter stenosis exceeding 90% in a coronary artery of at least 2.5 mm. The primary composite endpoint assessed all-cause mortality, myocardial infarction, or urgent revascularisation at one year.

Investigators found that performing PCI in CAD patients undergoing TAVI significantly reduced rates of death, MI or urgent revascularisation compared to TAVI alone. 

Interview Questions: 

1. What is the importance of the NOTION-3 trial?
2. What was the design, patient population and outcome measures of the study?
3. What are the key findings?
4. Did the trial reveal any unexpected results?
5. What are the take-home messages for practice?
6. How could this research shape future studies and guidelines?

Recorded on-site at ESC Congress 2024, London.

Editors: Jordan Rance and Mirjam Boros.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.